PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas 2) Amendable & assigned by the investigator to receive therapy with gemcitabine & nab-paclitaxel

You may not be eligible for this study if the following are true:

  • 1) Prior palliative treatment (e.g. surgery, radiation) to the tumor 2) Cancer requiring anti-tumor treatment within the 5 years before inclusion, excluding treated stage I prostate cancer, in situ cervical or uterus cancer, in situ breast cancer and non-melanomatous skin cancer. 3) Concurrent anti-tumor therapy beyond gemcitabine and nab-paclitaxel 4) Implantable electronic medical devices in the torso, such as pacemakers

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.